Review: Antiplatelet Drugs: What Comes Next?
Open Access
- 15 November 2010
- journal article
- review article
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 17 (1) , 9-26
Abstract
Antiplatelet drugs are important components in the management of atherothrombotic vascular disease. However, several limitations restrict the safety and efficacy of current antiplatelet therapy in clinical practice. Interpatient variability and resistance to aspirin and/or clopidogrel has spurred efforts for the development of novel agents. Indeed, several antiplatelet drugs are at various stages of evaluation; those at advanced stage of development are the focus of this review.Keywords
This publication has 120 references indexed in Scilit:
- Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The Early Rapid ReversAl of Platelet ThromboSis with Intravenous Elinogrel before PCI to Optimize REperfusion in Acute Myocardial Infarction (ERASE MI) pilot trialAmerican Heart Journal, 2009
- Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 2009
- Effect of the Thromboxane Prostaglandin Receptor Antagonist Terutroban on Arterial Thrombogenesis after Repeated Administration in Patients Treated for the Prevention of Ischemic StrokeCerebrovascular Diseases, 2009
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJAMA, 2009
- Increased Endothelial Nitric-Oxide Synthase Expression Reduces Hypertension and Hyperinsulinemia in Fructose-Treated RatsThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trialEuropean Heart Journal, 2008
- Par4 is required for platelet thrombus propagation but not fibrin generation in a mouse model of thrombosisProceedings of the National Academy of Sciences, 2007
- Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trialAmerican Heart Journal, 2006
- Platelets and cancer metastasis: A causal relationship?Cancer and Metastasis Reviews, 1992
- The role of nitric oxide and cGMP in platelet adhesion to vascular endotheliumBiochemical and Biophysical Research Communications, 1987